Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Principia Biopharma Inc.

Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, has created a revolutionary new way to design and develop oral small molecule therapies that are more potent, selective, durable and safer than currently available drugs. The Company has utilized its proprietary Tailored Covalency™ technology to develop a portfolio of drug candidates that exhibit antibody-like specificity to benefit patients with autoimmune and inflammatory diseases and cancer. PRN1008, a reversible covalent BTK inhibitor, is currently being evaluated in a Phase 2 clinical trial in patients with pemphigus, an orphan autoimmune disease. PRN1371, a covalent FGFR1-4 inhibitor, is currently being evaluated in a Phase 1 clinical trial in cancer patients with various solid tumors. PRN2246, a low dose covalent BTK inhibitor which crosses the blood brain barrier, recently has initiated a Phase 1 clinical trial in healthy volunteers. *


Period Start 2013-04-06 existent
Products Industry cancer drug
  Industry 2 MS DRUGS
  Street 400 East Jamie Court
  City 94080 South San Francisco, CA
  Tel +1-650-416-7700
    Address record changed: 2017-11-17
Basic data Employees n. a.
    * Document for �About Section�: Sanofi S.A.. (11/9/17). "Press Release: Sanofi, Principia Agree to Develop Multiple Sclerosis Drug Candidate". Paris & South San Francisco, CA.
Record changed: 2018-10-31


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Principia Biopharma Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top